- AMGN -0.22%
Search results
- 305.84Add to watchlist-0.66 (-0.22%)At close: Fri. May 24, 2024 4:00 PM EDT · Nasdaq Real Time Price (USD) · Market closed
- Open306.42High307.50Low303.90
- Mkt Cap164.06BP/E (TTM)43.69Div & Yield9.00 & 2.94%
- Prev. Close306.5052 Wk. Low211.7152 Wk. High329.72
What analysts are sayingTop storiesIt's Unlikely That Amgen Inc.'s (NASDAQ:AMGN) CEO Will See A Huge Pay Rise This YearYahoo Finance · 1 day agoThe Biggest Publicly Traded Biotech CompanyYahoo Finance · 21 hours agoAmgen/AstraZeneca Say Asthma Drug Shows Activity In Another Lung Disease Across Broad Patient PopulationYahoo Finance · 6 days agoRelated stocks
AMAT Applied Materials, Inc. 217.95. -0.09%. Find the latest Amgen Inc. (AMGN) stock quote, history, news and other vital information to help you with your stock trading and investing.
Amgen Inc. (formerly Applied Molecular Genetics Inc.) is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. [3] [4] One of the world's largest independent biotechnology companies, Amgen's Thousand Oaks staff in 2022 numbered approximately 5,000 [5] (8.5% of total city employment) [6] and included ...
Live. Win. Thrive. We dare to ask questions that lead to lifesaving treatments. Join us in pushing the boundaries of biotechnology in a career at Amgen.
For product questions, to report an adverse event or safety-related issue, or to report a quality issue with a product or device. U.S. healthcare professionals can also visit amgenmedinfo.com. Local contact information by country can be found here. +1 800-772-6436 (800-77-AMGEN)
Jan 31, 2023 · THOUSAND OAKS, Calif., Jan. 31, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced AMJEVITA™ (adalimumab-atto), a biosimilar to Humira ®* (adalimumab), is now available in the United States. AMJEVITA was the first biosimilar to Humira approved by the U.S. Food and Drug Administration (FDA), in 2016. 2,3.
Feb 6, 2024 · About Amgen. Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of ...
Amgen | 1,200,625 followers on LinkedIn. #WeareBiotech | Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing ...